



(11) **EP 2 991 618 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/00 ^(2006.01) **A61K 31/505** ^(2006.01)
A61K 9/08 ^(2006.01) **A61K 47/12** ^(2006.01)
A61K 47/24 ^(2006.01)

(48) Corrigendum issued on:
15.05.2019 Bulletin 2019/20

(86) International application number:
PCT/EP2014/001152

(45) Date of publication and mention
of the grant of the patent:
09.01.2019 Bulletin 2019/02

(87) International publication number:
WO 2014/177273 (06.11.2014 Gazette 2014/45)

(21) Application number: **14721211.2**

(22) Date of filing: **30.04.2014**

(54) **STABLE HIGH STRENGTH PHARMACEUTICAL COMPOSITION OF LEVOLEUCOVORIN**

STABILE HOCHDOSIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND
LEVOLEUCOVORIN

COMPOSITION STABLE À UNE DOSE ÉLEVÉE CONTENANT LEVOLEUCOVORINE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **30.04.2013 EP 13002298**

(43) Date of publication of application:
09.03.2016 Bulletin 2016/10

(73) Proprietor: **Aprofol AG**
9050 Appenzell Steinegg (CH)

(72) Inventor: **ULMANN, Martin**
CH-8447 Dachsen (CH)

(74) Representative: **Althaus, Roland**
Suisse Technology Partners AG
Querstrasse 5
8212 Neuhausen am Rheinfall (CH)

(56) References cited:
WO-A1-2010/043050 WO-A2-2004/112761
US-A- 4 931 441

EP 2 991 618 B8

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).